SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending primarily due to market frustration over a combined $3 billion convertible note offering and an at-the-market equity program, which traders view as highly dilutive despite the company's strong compute demand and multi-billion dollar customer backlog. While some investors see the pullback as a buying opportunity given the firm's growth, others are criticizing the management team's timing and citing concerns over the company's debt-heavy capital structure.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as traders speculate on positive guidance and upcoming Phase 2 lung cancer data, fueled by the company's strong commercial momentum and recently confirmed clear line of sight to profitability. The community remains largely bullish, focusing on long-term platform expansion, institutional accumulation, and the expectation that the stock's transition toward a solid tumor powerhouse warrants a significant re-rating.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors speculate on potential catalysts related to the company's immunotherapy pipeline and the recent investment by billionaire Patrick Soon-Shiong in a partner biotech, PDS Biotechnology. Discussion is heavily focused on expectations for a future short squeeze, frustration with short selling activity, and anticipation of upcoming trial data and FDA-related announcements.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending as traders speculate on the potential for a major short squeeze, driven by sentiment that the stock remains deeply undervalued relative to its growth and peers despite recent price volatility. While some participants focus on technical support levels and high short interest, others express frustration with the stock's failure to maintain momentum and its sensitivity to broader market movements.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry shares are seeing active trading and sentiment shifts as investors position themselves ahead of the upcoming earnings report. The community is actively discussing the company's growth prospects, particularly regarding its QNX software and Radar platform, while debating the efficacy of current management.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending as investors react to the CEO's comments regarding persistent challenges in stabilizing 737 production and ongoing supply-chain constraints. While some traders view the resulting sell-off as an overreaction, others remain bearish, citing production delays and potential labor-related risks.

Generac Holdings, Inc. engages in the business of designing and manufacturing energy technology solutions. It operates under the Domestic and International segments. The Domestic segment includes the legacy Generac business and the acquisitions that are based in the United States and Canada. The International segment focuses on Generac business' Latin American export operations. The company was founded in 1959 and is headquartered in Waukesha, WI.

Generac Holdings Inc

Generac is trending after entering a long-term supply agreement with Amazon to provide backup power for its data centers, a deal analysts believe could unlock significant long-term order volume. While the stock saw significant volatility following the announcement, community discussion remains focused on the company's emerging role as a critical infrastructure player for AI and data center capacity.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending after announcing an on-demand GPU price hike effective October 1, which the community interprets as a signal of continued strong demand for its AI infrastructure despite sector-wide volatility. Traders are debating the stock's price action, with many viewing recent dips as buying opportunities and dismissing concerns about sector-wide dilution or negative sentiment from competitors.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel shares are trending following a Reuters report detailing exploratory discussions regarding a potential partnership with SK Hynix to manufacture memory chips in the U.S., possibly utilizing Intel's Ohio facility. While the community is debating the impact of the news and the potential for a formal agreement, sentiment remains mixed between optimism over the strategic partnership potential and skepticism regarding the current lack of a finalized deal.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is trending following strong upward momentum driven by the company's role in supporting Moderna's successful Phase 3 trial for a personalized cancer vaccine, which validates its integration of genomic sequencing and precision medicine. While bulls anticipate a potential short squeeze due to high short interest and institutional accumulation, some traders remain cautious, debating the company's valuation and the strategic implications of its acquisition of Personalis.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Quanterix Names Dr. Yuri Fesko Chief Medical Officer

Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that accomplished physician executive Dr. Yuri Fesko has been appointed Chief Medical Officer of the company. In this new role, he will provide medical and clinical leadership across Quanterix...

Quanterix (QTRX) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

12 Health Care Stocks Moving In Friday's After-Market Session

Gainers

iTonic Holdings (NASDAQ:ITOC) stock moved upwards by 32.0% to $0.41 during Friday's after-market session. The company's market cap stands at $4.9 million.
Quanterix (NASDAQ:QTRX) shares increased byread more...

Quanterix Q2 Earnings Call Highlights

Quanterix Names Jim Gute Chief Commercial Officer

Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that seasoned healthcare executive Jim Gute has been appointed Chief Commercial Officer of the company. In this role, he will lead a re-acceleration of growth within the companys commercial...

Quanterix Releases Financial Results for the Second Quarter of 2026

Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced financial results for the second quarter ended June 30, 2026. We made meaningful progress in the second quarter, including strengthening our leadership team and preserving cash better than planned...

Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12

Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that senior management will participate in the Canaccord Genuity Capital Markets 46th Annual Growth Conference at the Intercontinental Hotel in Boston on August 11-12, 2026. Chief Executive Officer...

Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026

Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, August 10, 2026, at 8:30 AM ET, to discuss its second quarter 2026 financial results. Quanterix will issue a press release regarding its second...

Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Quanterix Corporation (Quanterix or the Company) (NASDAQ: QTRX), a global leader in precision biomarker science, today announced that on July 15, 2026, an inducement grant (the Inducement Grant) was made to Jason Faessler in connection with the commencement of his employment as the Chief Financial...

Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages

Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimers testing. Together, these milestones reinforce the growing role of LucentAD Complete, Quanterixs...

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.

Quanterix Corp

TRIB, QTRX, RCON: Why These Stocks Are Surging After-Hours Today 

Equity

Bullish Sentiment

No more this year

One more

Two more

The Federal Reserve raised interest rates by a quarter point to a range of 3.75%-4.00% on Wednesday, its first hike since July 2023, but Fed Chair Kevin Warsh signaled the tightening cycle isn't over. How many more rate hikes do you expect by the end of 2026? Vote and explain your reasoning in the comments.

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it&#39;s not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Stocktwits

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it's not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.43	--	--	N/A
Q2 '26	-$0.41	-$1.04	-153.66%	MISSED
Q1 '26	-$0.51	-$0.37	27.92%	BEAT
Q4 '25	-$0.45	-$0.49	-9.16%	MISSED
Q3 '25	-$0.46	-$0.73	-59.56%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

QTRX Earnings

Upcoming Earnings: Q3 '26

Historical Earnings